PMID- 31937933
OWN - NLM
STAT- MEDLINE
DCOM- 20210209
LR  - 20210210
IS  - 1745-7254 (Electronic)
IS  - 1671-4083 (Print)
IS  - 1671-4083 (Linking)
VI  - 41
IP  - 5
DP  - 2020 May
TI  - Fecal microbiota transplantation improves metabolism and gut microbiome 
      composition in db/db mice.
PG  - 678-685
LID - 10.1038/s41401-019-0330-9 [doi]
AB  - Fecal microbiota transplantation (FMT) has become an effective strategy to treat 
      metabolic diseases, including type 2 diabetes mellitus (T2DM). We previously 
      reported that the intestinal microbiome had significant difference between 
      individuals with normal glucose tolerance and T2DM in Chinese Kazak ethnic group. 
      In this study, we investigated the effects of transplanted fecal bacteria from 
      Kazaks with normal glucose tolerance (KNGT) in db/db mice. The mice were treated 
      with 0.2 mL of fecal bacteria solution from KNGT daily for 10 weeks. We showed 
      that the fecal bacteria from KNGT successfully colonized in the intestinal tract 
      of db/db mice detected on day 14. In the FMT-treated db/db mice, the levels of 
      fasting blood glucose, postprandial glucose, total cholesterol, triglyceride, and 
      low-density lipoprotein-cholesterol were significantly downregulated, whereas 
      high-density lipoprotein-cholesterol levels were upregulated. In the FMT-treated 
      db/db mice, Desulfovibrio and Clostridium coccoides levels in gut were 
      significantly decreased, but the fecal levels of Akkermansia muciniphila and 
      colon histone deacetylase-3 (HDAC3) protein expression were increased. At 8 
      weeks, both intestinal target bacteria and HDAC3 were correlated with glycolipid 
      levels; Akkermansia muciniphila level was positively correlated with HDAC3 
      protein expression (r = +0.620, P = 0.037). Our results suggest that fecal 
      bacteria from KNGT could potentially be used to treat diabetic patients.
FAU - Zhang, Pei-Pei
AU  - Zhang PP
AD  - Department of Pharmacology, Xinjiang Medical University, Urumqi, 830000, China.
FAU - Li, Lin-Lin
AU  - Li LL
AD  - Department of Pharmacology, Xinjiang Medical University, Urumqi, 830000, China.
AD  - State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence 
      Diseases in Central Asia of Xinjiang Medical University, Urumqi, 830000, China.
FAU - Han, Xue
AU  - Han X
AD  - Department of Pharmacology, Xinjiang Medical University, Urumqi, 830000, China.
FAU - Li, Qin-Wei
AU  - Li QW
AD  - Department of Otorhinolaryngology, Heze Municipal Hospital, Heze, 274031, China.
FAU - Zhang, Xu-Hua
AU  - Zhang XH
AD  - Department of Pharmacology, Xinjiang Medical University, Urumqi, 830000, China.
FAU - Liu, Johnson J
AU  - Liu JJ
AD  - Department of Pharmacology, School of Medical Sciences, Faculty of Medicine, 
      University of New South Wales, Sydney, NSW, Australia.
FAU - Wang, Ye
AU  - Wang Y
AD  - Department of Pharmacology, Xinjiang Medical University, Urumqi, 830000, China. 
      wangye56@xjmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20200114
PL  - United States
TA  - Acta Pharmacol Sin
JT  - Acta pharmacologica Sinica
JID - 100956087
RN  - Akkermansia muciniphila
RN  - Blautia coccoides
SB  - IM
MH  - Akkermansia/metabolism
MH  - Animals
MH  - Clostridiales/*metabolism
MH  - Desulfovibrio/*metabolism
MH  - Diabetes Mellitus, Type 2/*metabolism/therapy
MH  - Disease Models, Animal
MH  - Dyslipidemias/*metabolism/therapy
MH  - *Fecal Microbiota Transplantation
MH  - *Gastrointestinal Microbiome
MH  - Humans
MH  - Male
MH  - Mice
PMC - PMC7468362
OTO - NOTNLM
OT  - Akkermansia muciniphila
OT  - Chinese Kazak ethnic group
OT  - Clostridium coccoides
OT  - Desulfovibrio
OT  - colon histone deacetylase-3
OT  - db/db mice
OT  - fecal microbial transplantation
OT  - intestinal microbiome
OT  - metabolic diseases
COIS- The authors declare no competing interests.
EDAT- 2020/01/16 06:00
MHDA- 2021/02/10 06:00
PMCR- 2021/05/01
CRDT- 2020/01/16 06:00
PHST- 2019/04/08 00:00 [received]
PHST- 2019/11/01 00:00 [accepted]
PHST- 2020/01/16 06:00 [pubmed]
PHST- 2021/02/10 06:00 [medline]
PHST- 2020/01/16 06:00 [entrez]
PHST- 2021/05/01 00:00 [pmc-release]
AID - 10.1038/s41401-019-0330-9 [pii]
AID - 330 [pii]
AID - 10.1038/s41401-019-0330-9 [doi]
PST - ppublish
SO  - Acta Pharmacol Sin. 2020 May;41(5):678-685. doi: 10.1038/s41401-019-0330-9. Epub 
      2020 Jan 14.